Estrella ImmunopharmaESLA
13F holders, Q2 2026 (June 30)15holders −1
2new positions
3sold out
1famous investor
$1.04avg. 13F price*
At the end of Q2 2026, 15 institutions reported holding Estrella Immunopharma Inc. (ESLA) in their 13F filings, down 1 from Q1 2026. 2 opened new positions and 3 sold out. The largest holders were Armistice Capital, LLC ($4.1M), Vanguard Capital Management LLC ($434K) and Geode Capital Management, LLC ($147K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Estrella Immunopharma Inc.
- CUSIP
- 297584104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $133 |
| Exits | 3 | $287K |
All 13F filers, Q1 2026 → Q2 2026: 64,987 shares bought and 449,537 shares sold, net −384,550 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Armistice Capital, LLC | 0.11% | Reduce -3.0% | 3,975,220 | $4.1M |
| Vanguard Capital Management LLC | 0.00% | Add +9.0% | 416,852 | $434K |
| Geode Capital Management, LLC | 0.00% | Reduce -10.3% | 141,321 | $147K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 64,921 | $68K |
| BlackRock, Inc. | 0.00% | Add +30.4% | 52,033 | $54K |
| State Street Corp. | 0.00% | No change | 43,252 | $45K |
| Renaissance Technologies | 0.00% | Reduce -37.7% | 39,100 | $41K |
| Northern Trust Corp. | 0.00% | Add +77.6% | 34,861 | $36K |
| US Bancorp \de | 0.00% | Add +18.3% | 20,000 | $21K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -31.9% | 3,308 | $3K |
| UBS Group AG | 0.00% | Reduce -88.6% | 1,721 | $2K |
| Toronto Dominion Bank | 0.00% | No change | 1,089 | $1K |
| Wolverine Asset Management LLC | 0.00% | No change | 468 | $487 |
| Barclays PLC | 0.00% | New | 126 | $131 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 2 | $2 |
"% of holder's portfolio" is ESLA's weight in each manager's 13F, not the share of Estrella Immunopharma Inc. the manager owns.